{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T02:52:27Z","timestamp":1792810347547,"version":"4.5.0"},"reference-count":116,"publisher":"Wiley","issue":"S278","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Acta Ophthalmologica"],"published-print":{"date-parts":[[2023,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    <jats:bold>ENGLISH SUMMARY:<\/jats:bold>\n                    Glaucoma is a leading cause of the global prevalence of irreversible blindness. The pathogenesis of glaucoma is not entirely known, but the major risk factors include advancing age, genetic predisposition, and increased intraocular pressure (IOP). The only evidence\u2010based treatment is a lowering of IOP through the use of eye drops, laser procedures, or surgical interventions. Although laser treatment is gaining recognition as a first\u2010choice treatment option, the most common approach for managing glaucoma is IOP\u2010lowering eye drops. A major challenge in the treatment is the occurrence of adverse events and poor adherence. In this context, the ocular surface is an area of great concern, as most glaucoma patients have dry eye disease (DED), which is largely caused by eye drops. Preservation with benzalkonium chloride (BAK) is a controversial topic due to its potential role as a significant cause of DED. A systematic review and meta\u2010analyses investigate potential differences in efficacy and safety between BAK\u2010preserved and BAK\u2010free anti\u2010glaucomatous eye drops (I). Many of the included studies report on ocular surface damage caused by the application of BAK\u2010preserved eye drops. However, the meta\u2010analyses addressing hyperemia, number of ocular adverse events, and tear break\u2010up time did not identify any significant differences. The latter is likely due to varying measurement methods, different endpoints, and study durations. It is, therefore, possible that the large variations between the studies conceal differences in the safety profiles. The efficacy meta\u2010analysis finds that there are no differences in the IOP\u2010lowering effect between BAK\u2010preserved and BAK\u2010free eye drops, indicating that BAK is not necessary for the effectiveness of eye drops. To promote more homogeneous choices of endpoints and methods when evaluating BAK\u2010preserved and BAK\u2010free glaucoma treatments, a Delphi consensus statement was performed. In this study, glaucoma experts and ocular surface disease experts reached consensus on the key factors to consider when designing such studies (II). The hope is to have more studies with comparable endpoints that can systematically show the potentially adverse effects of BAK. The preclinical studies in the current Ph.D. research focus on conjunctival goblet cells (GCs). GCs are important for the ocular surface because they release the mucin MUC5AC, which is an essential component of the inner layer of the tear film. BAK preservation may damage the GCs and result in a low GC density, leading to an unstable tear film and DED. The most commonly used IOP\u2010lowering drugs are prostaglandin analogs (PGAs). Thus, the conducted studies investigate the effect of PGAs preserved in different ways on GCs. BAK\u2010preserved latanoprost is cytotoxic to primary cultured human conjunctival GCs and results in a scattered expression of MUC5AC, in contrast to negative controls, where MUC5AC is localized around the cell nucleus (III). Preservative\u2010free (PF) latanoprost is not cytotoxic and does not affect the MUC5AC expression pattern. Furthermore, BAK\u2010preserved travoprost is found to be cytotoxic in a time\u2010dependent manner, while Polyquad\u00ae\u2010preserved travoprost does not affect GC survival at any measured time point (IV). Both Polyquad and BAK induce scattered expression of MUC5AC. The cytotoxicity of BAK\u2010preserved PGA eye drops is higher compared to the safer profile of PF and Polyquad\u2010preserved PGA eye drops (V). Additionally, PF latanoprost does not increase the release of the inflammatory markers interleukin (IL)\u20106 and IL\u20108, unlike BAK\u2010preserved latanoprost. A review highlights the active and inactive components of IOP\u2010lowering eye drops (VI). Several preclinical and clinical studies have identified adverse effects of BAK. Although other components, such as the active drug and phosphates, can also cause adverse events, the review clearly states that BAK alone is a major source of decreased tolerability. The conclusion of this thesis is that BAK preservation is unnecessary and harmful to the ocular surface. The preclinical studies demonstrate that GCs die when exposed to BAK. Furthermore, they find that BAK induces a pro\u2010inflammatory response. The review included in the thesis concludes that BAK should be phased out of eye drops for chronic use. Overall, the inclusion of BAK poses a risk of developing DED and poor adherence, which can ultimately lead to disease progression and blindness.\n                  <\/jats:p>","DOI":"10.1111\/aos.15808","type":"journal-article","created":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T03:00:29Z","timestamp":1701399629000},"page":"3-21","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["The use of benzalkonium chloride in topical glaucoma treatment"],"prefix":"10.1111","volume":"101","author":[{"given":"Anne Hedengran","family":"Nagstrup","sequence":"first","affiliation":[{"name":"Department of Drug Design and Pharmacology University of Copenhagen  Copenhagen Denmark"},{"name":"Department of Ophthalmology Copenhagen University Hospital\u2014Rigshospitalet  Copenhagen Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,12]]},"reference":[{"key":"e_1_2_13_2_1","doi-asserted-by":"publisher","DOI":"10.2174\/1874364101408010067"},{"key":"e_1_2_13_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1755-3768.2012.02565.x"},{"key":"e_1_2_13_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtos.2019.12.006"},{"key":"e_1_2_13_5_1","doi-asserted-by":"publisher","DOI":"10.2147\/JEP.S259297"},{"key":"e_1_2_13_6_1","doi-asserted-by":"publisher","DOI":"10.5114\/ceji.2016.60995"},{"key":"e_1_2_13_7_1","article-title":"Persistence and adherence with Latanoprost: a Danish register\u2010based cohort study in older patients with glaucoma","volume":"10","author":"Amiri D.","year":"2023","journal-title":"Acta Ophthalmologica"},{"key":"e_1_2_13_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-010-0070-1"},{"key":"e_1_2_13_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-011-0029-x"},{"key":"e_1_2_13_10_1","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2016.1202818"},{"key":"e_1_2_13_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.exer.2011.04.002"},{"key":"e_1_2_13_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2022.106315"},{"key":"e_1_2_13_13_1","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S13406"},{"key":"e_1_2_13_14_1","doi-asserted-by":"publisher","DOI":"10.4265\/bio.17.115"},{"key":"e_1_2_13_15_1","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/460483"},{"key":"e_1_2_13_16_1","first-page":"40","article-title":"In vitro and in\u00a0vivo experimental studies on trabecular meshwork degeneration induced by benzalkonium chloride (an American Ophthalmological Society thesis)","volume":"110","author":"Baudouin C.","year":"2012","journal-title":"Transactions of the American Ophthalmological Society"},{"key":"e_1_2_13_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2010.03.001"},{"key":"e_1_2_13_18_1","unstructured":"BD Life Sciences. (2019)BD cytometric bead array (CBA) human inflammatory cytokines kit. Available from:https:\/\/www.bdbiosciences.com\/content\/dam\/bdb\/products\/global\/reagents\/immunoassay\u2010reagents\/cba\/cba\u2010kits\/551xxx\/5518xx\/551811_base\/pdf\/551811_Book_Website.pdf[Accessed 4th September 2023]"},{"key":"e_1_2_13_19_1","doi-asserted-by":"publisher","DOI":"10.1097\/IJG.0b013e31825af67d"},{"key":"e_1_2_13_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tiv.2017.02.006"},{"key":"e_1_2_13_21_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0050180"},{"key":"e_1_2_13_22_1","doi-asserted-by":"publisher","DOI":"10.3109\/02713683.2011.578781"},{"key":"e_1_2_13_23_1","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2010.0111"},{"key":"e_1_2_13_24_1","doi-asserted-by":"publisher","DOI":"10.2165\/00002512-199202030-00005"},{"key":"e_1_2_13_25_1","volume-title":"Muscarinic agonists","author":"Bui T.","year":"2023"},{"key":"e_1_2_13_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2016.12.004"},{"key":"e_1_2_13_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/ceo.12390"},{"key":"e_1_2_13_28_1","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/636812"},{"key":"e_1_2_13_29_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0120284"},{"key":"e_1_2_13_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtos.2017.05.008"},{"key":"e_1_2_13_31_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-013-0014-7"},{"key":"e_1_2_13_32_1","unstructured":"Danish Medicines Agency. (2019)Product summary for Travoprost Stada. Available from:https:\/\/view.officeapps.live.com\/op\/view.aspx?src=https%3A%2F%2Fspcweb.produktresume.dk%2FSPCREPL%2FHuman%2FT%2FTravoprost%2520Stada%2C%2520%25c3%25b8jendr%25c3%25a5ber%2C%2520opl%25c3%25b8sning%252040%2520mikrogram\u2010ml.docx&wdOrigin=BROWSELINK[Accessed 4th September 2023]"},{"key":"e_1_2_13_33_1","unstructured":"Danish Medicines Agency. (2021a)Product summary for Bondulc. Available from:https:\/\/view.officeapps.live.com\/op\/view.aspx?src=https%3A%2F%2Fspcweb.produktresume.dk%2FSPCREPL%2FHuman%2FB%2FBondulc%2C%2520%25c3%25b8jendr%25c3%25a5ber%2C%2520opl%25c3%25b8sning%252040%2520mikrogram\u2010ml.docx&wdOrigin=BROWSELINK[Accessed 4th September 2023]"},{"key":"e_1_2_13_34_1","unstructured":"Danish Medicines Agency. (2021b)Product summary for Travoprost Teva. Available from:https:\/\/view.officeapps.live.com\/op\/view.aspx?src=https%3A%2F%2Fspcweb.produktresume.dk%2FSPCREPL%2FHuman%2FT%2FTravoprost%2520Teva%2C%2520%25c3%25b8jendr%25c3%25a5ber%2C%2520opl%25c3%25b8sning%252040%2520mikrogram\u2010ml.docx&wdOrigin=BROWSELINK[Accessed on 4th September 2023]"},{"key":"e_1_2_13_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.exer.2013.10.008"},{"key":"e_1_2_13_36_1","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.16-20903"},{"key":"e_1_2_13_37_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-5224.2004.00325.x"},{"key":"e_1_2_13_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/0022-1759(88)90310-9"},{"key":"e_1_2_13_39_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00216-013-6811-7"},{"issue":"10","key":"e_1_2_13_40_1","first-page":"2270","article-title":"Presence of nerves and their receptors in mouse and human conjunctival goblet cells","volume":"42","author":"Diebold Y.","year":"2001","journal-title":"Investigative Ophthalmology & Visual Science"},{"key":"e_1_2_13_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1542-0124(12)70082-4"},{"key":"e_1_2_13_42_1","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S176605"},{"key":"e_1_2_13_43_1","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2021-egsguidelines"},{"key":"e_1_2_13_44_1","unstructured":"European Medicines Agency. (2018)Summary of product characteristics Travatan. Available from:https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/travatan[Accessed 3rd August 2023]"},{"key":"e_1_2_13_45_1","unstructured":"European Medicines Agency. (2023a)Generic and hybrid medicines. Available from:https:\/\/www.ema.europa.eu\/en\/human\u2010regulatory\/marketing\u2010authorisation\/generic\u2010hybrid\u2010medicines[Accessed 12th July 2023]"},{"key":"e_1_2_13_46_1","unstructured":"European Medicines Agency. (2023b)Generic medicine. Available from:https:\/\/www.ema.europa.eu\/en\/glossary\/generic\u2010medicine. Accessed 12th July 2023"},{"key":"e_1_2_13_47_1","doi-asserted-by":"publisher","DOI":"10.1586\/17469899.4.1.59"},{"key":"e_1_2_13_48_1","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.01430307"},{"key":"e_1_2_13_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2022.09.009"},{"key":"e_1_2_13_50_1","doi-asserted-by":"publisher","DOI":"10.3109\/09273948.2011.618902"},{"key":"e_1_2_13_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2016.04.005"},{"key":"e_1_2_13_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1542-0124(12)70149-0"},{"key":"e_1_2_13_53_1","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.11-8748"},{"key":"e_1_2_13_54_1","unstructured":"Heegaard S. vanSetten G. Moilanen J. Kaarniranta K. Klyve P.&R\u00e6der S.(2022)Nordic Guidelines Second Edition 2022: Dry Eye Disease. Available from:https:\/\/dansk\u2010oftalmologisk\u2010selskab.dk\/wp\u2010content\/uploads\/2016\/09\/Nordic\u2010Guideline19\u201005.pdf[Accessed 4th September 2023]"},{"key":"e_1_2_13_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.exer.2012.08.010"},{"key":"e_1_2_13_56_1","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.17-23623"},{"key":"e_1_2_13_57_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-017-2270-8"},{"key":"e_1_2_13_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-7020-5193-7.00058-3"},{"key":"e_1_2_13_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yrtph.2013.03.014"},{"key":"e_1_2_13_60_1","doi-asserted-by":"publisher","DOI":"10.1177\/112067210701700311"},{"key":"e_1_2_13_61_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.exer.2016.01.017"},{"key":"e_1_2_13_62_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-008-0078-y"},{"key":"e_1_2_13_63_1","doi-asserted-by":"publisher","DOI":"10.1097\/ICO.0b013e31815cf651"},{"key":"e_1_2_13_64_1","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2014.0104"},{"key":"e_1_2_13_65_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajpcell.00582.2001"},{"key":"e_1_2_13_66_1","first-page":"91","article-title":"Mucous gland system of the conjunctiva. A quantitative normal anatomical study","volume":"95","author":"Kessing S.V.","year":"1968","journal-title":"Acta Ophthalmologica"},{"key":"e_1_2_13_67_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0132048"},{"key":"e_1_2_13_68_1","doi-asserted-by":"publisher","DOI":"10.1097\/IJG.0b013e318181284f"},{"key":"e_1_2_13_69_1","doi-asserted-by":"publisher","DOI":"10.22336\/rjo.2019.38"},{"key":"e_1_2_13_70_1","doi-asserted-by":"publisher","DOI":"10.4274\/tjo.galenos.2019.29000"},{"key":"e_1_2_13_71_1","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.120.3.330"},{"key":"e_1_2_13_72_1","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2006.22.267"},{"key":"e_1_2_13_73_1","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.12-9596"},{"key":"e_1_2_13_74_1","doi-asserted-by":"publisher","DOI":"10.1097\/IJG.0b013e31815c5f4f"},{"key":"e_1_2_13_75_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0033913"},{"key":"e_1_2_13_76_1","doi-asserted-by":"publisher","DOI":"10.1159\/000335984"},{"key":"e_1_2_13_77_1","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.2010.189449"},{"key":"e_1_2_13_78_1","first-page":"257","article-title":"A mouse dry eye model induced by topical administration of benzalkonium chloride","volume":"17","author":"Lin Z.","year":"2011","journal-title":"Molecular Vision"},{"key":"e_1_2_13_79_1","doi-asserted-by":"publisher","DOI":"10.1097\/ACI.0b013e32830e6b04"},{"key":"e_1_2_13_80_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpath.2013.03.017"},{"key":"e_1_2_13_81_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12253-014-9755-0"},{"key":"e_1_2_13_82_1","doi-asserted-by":"publisher","DOI":"10.1517\/13543776.2013.794788"},{"key":"e_1_2_13_83_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1542-0124(12)70138-6"},{"key":"e_1_2_13_84_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40123-022-00527-6"},{"issue":"5","key":"e_1_2_13_85_1","first-page":"71","article-title":"The pathophysiology, diagnosis, and treatment of dry eye disease","volume":"112","author":"Messmer E.M.","year":"2015","journal-title":"Deutsches \u00c4rzteblatt International"},{"key":"e_1_2_13_86_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2022.106206"},{"key":"e_1_2_13_87_1","doi-asserted-by":"publisher","DOI":"10.1016\/0022-1759(83)90303-4"},{"key":"e_1_2_13_88_1","doi-asserted-by":"publisher","DOI":"10.19082\/2954"},{"key":"e_1_2_13_89_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.ico.0000116526.57227.82"},{"key":"e_1_2_13_90_1","doi-asserted-by":"publisher","DOI":"10.1186\/1477\u20107525\u20101\u201075"},{"key":"e_1_2_13_91_1","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0000000000001800"},{"key":"e_1_2_13_92_1","doi-asserted-by":"publisher","DOI":"10.1128\/AEM.00377-19"},{"key":"e_1_2_13_93_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2013.05.027"},{"key":"e_1_2_13_94_1","doi-asserted-by":"publisher","DOI":"10.1111\/aos.12203"},{"issue":"8","key":"e_1_2_13_95_1","first-page":"4460","article-title":"How to deliver preservative\u2010free eye drops in a multidose system with a safer alternative to filters?","volume":"58","author":"Petit Ben Saidane L.","year":"2017","journal-title":"Investigative Ophthalmology and Visual Science"},{"key":"e_1_2_13_96_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19092760"},{"key":"e_1_2_13_97_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(97)30330-3"},{"key":"e_1_2_13_98_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12886-023-02838-z"},{"key":"e_1_2_13_99_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00165940"},{"key":"e_1_2_13_100_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21093111"},{"key":"e_1_2_13_101_1","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/8956504"},{"key":"e_1_2_13_102_1","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2012-302121"},{"key":"e_1_2_13_103_1","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2013.0248"},{"key":"e_1_2_13_104_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1237910"},{"key":"e_1_2_13_105_1","doi-asserted-by":"publisher","DOI":"10.1097\/ICO.0b013e318295a2a5"},{"key":"e_1_2_13_106_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2011.05.033"},{"key":"e_1_2_13_107_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtos.2019.11.005"},{"key":"e_1_2_13_108_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2014.05.013"},{"key":"e_1_2_13_109_1","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S150816"},{"key":"e_1_2_13_110_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2011.06.004"},{"key":"e_1_2_13_111_1","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.15-17455"},{"key":"e_1_2_13_112_1","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S211611"},{"key":"e_1_2_13_113_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yrtph.2013.09.006"},{"key":"e_1_2_13_114_1","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2009.0134"},{"key":"e_1_2_13_115_1","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2013.0179"},{"key":"e_1_2_13_116_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pathophys.2017.05.005"},{"key":"e_1_2_13_117_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jenvman.2013.04.056"}],"container-title":["Acta Ophthalmologica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/aos.15808","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,16]],"date-time":"2023-12-16T04:36:49Z","timestamp":1702701409000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/aos.15808"}},"subtitle":["An investigation of the efficacy and safety of benzalkonium chloride\u2010preserved intraocular pressure\u2010lowering eye drops and their effect on conjunctival goblet cells"],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":116,"journal-issue":{"issue":"S278","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["10.1111\/aos.15808"],"URL":"https:\/\/doi.org\/10.1111\/aos.15808","archive":["Portico"],"relation":{},"ISSN":["1755-375X","1755-3768"],"issn-type":[{"value":"1755-375X","type":"print"},{"value":"1755-3768","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"2023-12-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}